News

People with certain disabilities were found to be less likely to follow recommended guidelines for colorectal cancer screening.

Sixteen percent of patients with metastatic non-small cell lung cancer (NSCLC) receiving nivolumab survived after 5 years.

A shorter length of sleep may lead to an increased risk of death from prostate cancer, according to a recent study presented at the 2017 AACR Annual Meeting.

According to findings presented at the 2017 AACR Annual Meeting, aspirin use was associated with lower mortality in colorectal cancer.

Fewer people are dying from cancer than years ago, according to a recent study.

For patients with glioblastoma multiforme (GBM), tumor treating fields (TTFields) reduced the risk of death by 37% and extended overall survival by a median of 5 months.

For patients with cancer, smoking cessation should include counseling and pharmacology. Encouragement throughout, especially if a patient relapses is important.

A recent study found that individuals who had the chickenpox virus when they were younger were less likely to eventually develop gliomas.

Subcutaneous co-formulation of rituximab for treatment of patients with certain types of lymphoma and leukemia advances toward approval.

John E. Mullinax, M.D., discusses a chemotherapy strategy, isolated limb infusion, that may be able to save the limbs of some patients with sarcoma.

A recent study has found that pembrolizumab (Keytruda) may be effective in treating patients with mesothelioma.

Expert Adam M. Brufsky, MD, PhD, discusses the considerations for bone-targeted agents denosumab and zoledronic acid (Zometa) in patients with breast cancer.

Kula for Karma, a nonprofit organization, offers yoga programs designed to aid patients with cancer as well as medical professionals, first responders and others, manage stress and improve quality of life.

The FDA has issued an advisory on the association between breast implants and anaplastic large cell lymphoma. More research is needed in this area.

The FDA has granted approval for the PARP inhibitor niraparib for maintenance treatment of patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial repsponse to platinum-based chemotherapy.

For patients with breast cancer on aromatase inhibitors, preventive sexual counseling can reduce sexual dysfunction, and it should be provided earlier in treatment, with support from providers.

A recent study found that by using standardized criteria, a more objective assessment of patients and their families’ palliative care needs can be made, which can lead to improvement in multiple quality measures.

Today, the US House of Representatives is set to vote on the American Health Care Act which would repeal the Affordable Care Act, ACA or Obamacare.

The FDA has granted an accelerated approval to immunotherapy agent avelumab for the treatment of metastatic Merkel cell carcinoma.

For patients with BRCA+ ovarian cancer, olaparib in the maintenance setting has shown impressive progression free survival benefits.

A recent study found that out-of-pocket costs could be a barrier to timely initiation of TKI therapy among individuals with Medicare coverage.

On March 21, at 9 PM EST, the #CureConnect tweetchat will be focusing on screening and prevention. Sharyn Worrall, Patient Education Manager for FightCRC will be comoderating on this topic, which is especially important for colorectal cancer.

A recent study evaluated how muscle mass can be used to predict which patients will experience toxicities from chemotherapy and to what extent.

A recent study found that neurofeedback brain training could be effective in reducing chemotherapy-induced peripheral neuropathy (CIPN).

According to a recent survey, the main causes for a lack of HPV vaccine uptake are a lack of knowledge and a failure by healthcare providers to recommend it.

The FDA has granted accelerated approval to pembrolizumab for treatment of patients with hodgkin lymphoma.

The PARP inhibitor olaparib improved PFS when compared to standard chemotherapy in patients with BRCA-positive breast cancer, according to findings from the phase III OLYMPIAD trial.

The benfits of imatinib persisted over time and long-term administration of the drug was not assicationed with unacceptable toxic effects in patients with chronic myeloid leukemia (CML).

The FDA has granted approval to ribociclib (Kisqali) for firstline treatment of HR+/HER2- breast cancer.

According to findings presented at the 2017 Miami Breast Cancer Conference, combination eribulin and pembrolizumab showed promising results for patients with metastatic triple-negative breast cancer (TNBC).